Arrow Pharmaceuticals Limited v Merck and Co Inc

Link copied
Case Copied 46 min read

FEDERAL COURT OF AUSTRALIA

Arrow Pharmaceuticals Limited v Merck & Co Inc [2004] FCA 129

PRACTICE AND PROCEDURE – application revocation of Australian patent – whether particulars of invalidity adequate – lack of novelty and inventive steps alleged – subsequent amendment of particulars – discussion of privilege of medical practitioner – whether case as pleaded and particularised should proceed to trial.

Patents Act 1990 (Cth) s 7(1), (2), 18(1)
Evidence Act 1995 (Cth)

Terrell on the Law of Patents (15th ed) par 7.04
Federal Court Rules Order 58 rule 15

Stanway Oyster Cylinders Pty Ltd v Marks (1996) 35 IPR 71
Merrell Dow Pharmaceuticals Inc and Others v H.N. Norton & Co Ltd (1995) IPR 1
General Steel Industries Inc v Commissioner for Railways (NSW) (1964) 112 CLR 125
Dey v Victorian Railways Commissioners (1949) 78 CLR 62
Fomento Industrial SA., Biro Swan Ltd and Another v Mentmore Manufacturing Coy Ltd (1956) RPC 87
ICI Chemicals and Polymers Ltd v Lubrizol Corporation (1999) 45 IPR 577
Chiron Corporation v Organon Teknika Limited (No 3) [1994] FSR 202
RD Werner & Co Inc v Bailey Aluminium Products Pty Ltd (1989) 13 IPR 513
Conde Nast Publications Pty Ltd v Taylor (1998) 41 IPR 505
National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252
Minnesota Mining and Manufacturing Company v Beiersdorf (Australia) Limited (1980) 144 CLR 253
Sunbeam Corporation v Morphy-Richards (Aust) Pty Ltd (1961) 180 CLR 98
Merell Dow Pharmaceutical Inc v H.N. Norton & Co Ltd (1996) PRC 76
Windsurfing International Inc v Petit (1983-1985) 2 IPR 449 at 484-490

ARROW PHARMACEUTICALS LIMITED v MERCK AND CO INC

N 1211 OF 2002

CONTI J
23 FEBRUARY 2004
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 1211 OF 2002

BETWEEN:

ARROW PHARMACEUTICALS LIMITED
APPLICANT

AND:

MERCK & CO INC.
RESPONDENT

JUDGE:

CONTI J

DATE OF ORDER:

23 FEBRUARY 2004

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The respondent’s notice of motion filed on 10 November 2003 be dismissed otherwise than to the extent that the parties have mutually agreed.

2.The costs of the respondent’s applications the subject of the notice of motion be stood over for further submissions in the light of the reasons for judgment.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 1211 OF 2002

BETWEEN:

ARROW PHARMACEUTICALS LIMITED
APPLICANT

AND:

MERCK & CO INC.
RESPONDENT

JUDGE:

CONTI J

DATE:

23 FEBRUARY 2004

PLACE:

SYDNEY

REASONS FOR JUDGMENT

Background

  1. Subsequently to delivery of reasons for interlocutory judgment on 27 June 2003, the respondent Merck & Co Inc. (‘Merck’) sought the following relief against the applicant Arrow Pharmaceuticals Ltd (‘Arrow’) by notice of motion filed on 10 November 2003:

    (i)A declaration that the Further Amended Particulars of Invalidity filed by Arrow on 25 July 2003 and the further particulars set out in a letter dated 10 September 2003 from Arrow’s…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Arrow Pharmaceuticals Limited v Merck and Co Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCA 129
Decision Date

CaseChat Overview and Summary

In the case of Arrow Pharmaceuticals Limited v Merck and Co Inc, the dispute centred on whether Merck had breached confidentiality obligations and publicly disclosed prior art information, which Arrow claimed was protected under the relevant legislation. The matter was heard in the Federal Court of Australia, where the court had to determine the adequacy of particulars provided by Arrow regarding the prior art information and the extent to which Merck had made such information publicly available. The court also had to consider the implications of any potential patient privilege in the context of the medical practitioners' testimonies.

The primary legal issues that the court needed to address were the sufficiency of the particulars provided by Arrow in relation to the prior art information, and whether the acts identified by Arrow constituted a public disclosure of this information. The court further examined the application of Order 58 rule 15 of the Federal Court Rules, which governs the particularity required in affidavit evidence. The court had to decide whether the acts of the medical practitioners constituted the "occasion" for the application of this rule, and whether further discovery was necessary. Additionally, the court considered the potential applicability of patient privilege in the context of medical practitioners' treatment of unidentified sick or injured persons.

The court found that the December 2003 Particulars provided by Arrow appeared to comply adequately with Order 58 rule 15(2) concerning the professional conduct and practices of the medical practitioners. The court emphasised that the rule does not require an excessive level of specificity regarding the times, places, and other related circumstances of the issuance of prescriptions. The court held that the existence of any patient privilege would not apply to the treatment of unidentified sick or injured persons, as this would not intrude into the private affairs of any identifiable individual. The court dismissed the respondent's notice of motion, except to the extent that the parties had mutually agreed. The costs of the respondent's applications were stood over for further submissions in light of the reasons for judgment.

ORDERS:
1. The respondent’s notice of motion filed on 10 November 2003 is dismissed otherwise than to the extent that the parties have mutually agreed.
2. The costs of the respondent’s applications, which are the subject of the notice of motion, are stood over for further submissions in light of the reasons for judgment.

Orders

Orders of the court

1. The respondent’s notice of motion filed on 10 November 2003 be dismissed otherwise than to the extent that the parties have mutually agreed.

2. The costs of the respondent’s applications the subject of the notice of motion be stood over for further submissions in the light of the reasons for judgment.

Background

Background to the litigation

Arrow Pharmaceuticals Limited, the plaintiff, initiated legal proceedings against Merck and Co Inc, the defendant, in relation to alleged patent infringement concerning a pharmaceutical product used in the treatment of osteoporosis. The proceedings involved disputes over the adequacy of particulars provided by Arrow in relation to prior art information, which is information publicly available before a patent is granted. Arrow contended that the issue of whether certain acts made prior art information publicly available should be determined at trial. The case included evidence from medical practitioners about their professional conduct and practices in treating osteoporosis, including the prescription of alendronate sodium. Arrow also filed affidavit evidence concerning the professional conduct and practices of several doctors, as well as relevant medical journals. Merck challenged the adequacy of Arrow's particulars, particularly regarding the specificity of the times, places, and circumstances of the issuance of prescriptions. The court had to decide whether the particulars provided by Arrow were adequate under Order 58 rule 15 of the rules of court.

The matter came before the court through a notice of motion filed by Merck on 10 November 2003. This motion sought orders in relation to the adequacy of particulars provided by Arrow. The court heard arguments from both parties and reviewed the material evidence and submissions. The court examined the submissions from both sides, including the affidavit evidence from Arrow concerning the professional conduct and practices of the medical practitioners and the identification of relevant medical journals. The court also considered Merck's challenges to the adequacy of Arrow's particulars. The court examined the evolution of the parties' contentions and the procedural issues that arose, including the application of Order 58 rule 15.

Decision

Reasons for decision

CONTI J
Arrow therefore contended, apart from the issue as to the adequacy of particulars provided in the affidavit evidence already filed in relation to the making available of certain prior art information purportedly within s 7(1) of the Act, that whether the acts, which it had identified by its affidavit evidence, made prior art information thereby publicly available was one for determination at the trial of the proceedings upon the basis of all the evidence there made legitimately and realistically available. The Court’s conclusions I have reproduced at some length the respective submissions of the parties for two reasons, first in order that an appreciation of the evolution of their respective contentions in the context of disputes upon issues as to particularity are fully recorded for the purposes of procedural and evidentiary issues which may further arise; and secondly so that appropriate orders as to the costs of those disputes may be framed with the particularity required. It will be readily apparent from my tracing in chronological sequence of the events and areas of interlocutory disputation that Arrow has substantially enlarged upon the extent of its initial affidavit evidence, and of the particularity dictated by Order 58 rule 15, largely so it would seem as a consequence of the interlocutory steps initiated by Merck. Merck has also taken in my opinion the appropriate stance of drawing the Court’s attention to circumstances where issues as to the privilege of individual patients of medical practitioners may conceivably arise. It is apparent, from the material to which my attention has been drawn, that patient privilege akin to legal professional privilege may be open to be drawn in particular circumstances involving the relationship between medical practitioners and their patients concerning or involving matters of advice and treatment. However, I am of the view that the existence of any such privilege would not apply in principle to circumstances involving a medical practitioner’s treatment of at least unidentified sick or injured persons generally, being unidentified in the sense of non-disclosure of identity of any individual persons. In that kind of context, a medical practitioner would be testifying as to matters of professional practice, without intruding into the medical condition and affairs of any identified or identifiable private individual. The December 2003 Particulars evince in my opinion an apparent adequacy of compliance with Order 58 rule 15(2) in relation to the professional conduct and practices of each of Doctors Diamond, Sambrook, Martin, Hooper, Eden and Epstein, as well as in relation to identification of allegedly relevant medical professional journals. That is not to say that there may be room for further and better discovery on Arrow’s part, and perhaps also for that matter on Merck’s part. I would identify ‘the act’, for the purposes of the application of the rule, as an occasion or the occasion, when each medical practitioner undertook or performed the conduct of a professional nature constituting a procedure or practice as to treatment of osteoporosis, either by himself in person or by way of recommendation to a fellow practitioner. In circumstances such as have been here indicated by the evidence of the medical practitioners, I do not think that it is necessary or essential to specify with precision, for instance, the times, places and indeed some other related circumstances, of issue of each prescription of alendronate sodium. Otherwise relief of the kind here sought could be conceivably but unjustly rendered unattainable in any practical sense. In short, I do not think that the operation of Order 58 rule 15 is as inflexibly specific as the content or thrust of certain of Merck’s contentions might be inferentially construed to have put forward.

Ratio Decidendi

Legal Principle Established

Established by: CONTI J

The court thoroughly examined the submissions of both parties regarding the adequacy of particulars and the issue of public availability of prior art information. It found that Arrow's December 2003 Particulars met the requirements of Order 58 rule 15(2) in relation to the professional conduct of the medical practitioners and the identification of relevant medical journals. The court noted that while there may be room for further discovery, the current particulars were sufficient for the purposes of the application of the rule. Regarding the public availability of prior art information, the court concluded that this was a matter to be determined at trial based on all the evidence legitimately and realistically available. The court also considered the potential implications of patient privilege but found that it would not apply in the context of unidentified sick or injured persons. This decision highlights the court's approach to ensuring procedural fairness while allowing the case to progress to trial for a comprehensive examination of the facts.